Baricitinib for treating moderate to severe atopic dermatitis – guidance (TA681)

Baricitinib is recommended for moderate to severe atopic dermatitis in adults, only after lack of response to at least 1 systemic immunosuppressant. If inadequate response at 16 weeks (≤50% reduction in EASI score and 4 point reduction in DLQI), treatment should be stopped.

Source:

National Institute for Health and Care Excellence